The biopharmaceutical company plans to launch the first-ever crypto asset based on the Rain project. Enlivex believes that Rain’s open prediction market has long-term potential. Native RAI rallied on this news, rising 110% within minutes.
Cryptocurrency markets were relatively stable on Monday, with Bitcoin trading above $86,000.
While most assets saw small price movements, RAIN broke away from the sharp uptrend.
The altcoin rose around 110% minutes after news that biopharmaceutical company Enlivex Therapeutics plans to build a $212 million Rain-based crypto asset.
News: ENLIVEX has completed a $212 million digital asset financial investment in $RAIN, a decentralized prediction market protocol pioneering the next wave of prediction markets. Former Italian Prime Minister Matteo Renzi has joined the Board of Directors.
— Ash Crypto (@AshCrypto) November 24, 2025
According to reports, the Nasdaq-listed company plans to complete the financing through a PIPE (private investment in public equity).
Notably, Enlivex will be the first institution to create a DAT (Digital Asset Treasury) linked to a prediction market crypto project.
The proposed raise includes Enlivex selling 212 million shares at $1 per share, to be settled in USDT and US dollars.
Meanwhile, the deal is expected to close by November 25, subject to final approval.
For a company focused on immunotherapy research, dedicating millions of dollars to crypto reflects a bold move to blockchain infrastructure.
Additionally, this move increases RAIN’s credibility as a legitimate token with significant value in the financial world.
This update reversed RAIN coin sentiment, causing a sharp rise minutes after the news surfaced.
Why make such a bold bet on Rain?
In an interview with The Block, Enlivex Board Chairman Shai Novik emphasized that Rain’s infrastructure is the scalable backbone the company has been pursuing.
He compared Rain’s dominance in prediction markets to Uniswap in decentralized trading. Novik said:
For us, its open architecture model represents the scalable growth engine we were looking for. We see Rain as a foundational infrastructure layer for the industry, similar to how Uniswap underpins decentralized trading.
So Enlivex doesn’t just buy RAIN.
Biopharmaceutical companies are investing in decentralized predictive market models that aim to transform on-chain information markets.
A unique approach to reducing volatility
In fact, cryptocurrencies and volatility are closely related, which has prevented many institutional investors from interacting with digital tokens.
In that context, the Rain Foundation will support Enlivex’s DAT launch with a grant that will adjust the company’s entry price with an initial mNAV (modified net asset value) of 0.95.
This reduced early-stage volatility as biopharmaceutical companies had a stable baseline from which to launch their DAT strategies.
RAIN price outlook
Rain’s native token led today’s gains.
The coin is trading at $0.007526 after rising 110% on the daily price chart.
A 66% increase in 24-hour trading volume shows that demand on RAIN is on the rise again.
Although Alteyes continues to trend higher, it is unlikely to break away in the long term as widespread selling pressure prevails.
Therefore, RAIN remains likely to erase some of its gains in the short term.
